Sign inJoin waitlistJoin the waitlist

AA

Amon Asgharpour

Physician · Virginia Commonwealth University School of Medicine

Credentials: · · · · · ·

History

Virginia Commonwealth University School of Medicine
2021–Present

Transplant Hepatology
Virginia Commonwealth University Health System
2016–2017
Gastroenterology
Virginia Commonwealth University Health System
2013–2016
Internal Medicine
SUNY Downstate Health Sciences University
2009–2012
Ross University School of Medicine
2005–2009

Research

A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
Journal of Hepatology · 2016 · First of 18 authors · 431 citations
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease
JAMA · 2024 · 221 citations
Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease
Scientific Reports · 2019 · 141 citations

Arun Sanyal
41 papers
Michelle Lai
23 papers
Shadab Siddiqui
9 papers · 8 as a fellow
VP
Vaishali Patel
6 papers
Eric Houpt
5 papers
Richard Sterling
5 papers
RV
Robert Vincent
5 papers · 4 as a fellow
Scott Matherly
5 papers
Barham Abu Dayyeh
4 papers
FB
Fateh Bazerbachi
4 papers
JW
Joel Wedd
4 papers
Melissa Contos
4 papers

Clinical trials

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2032
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
Site PI · Recruiting · Phase 2
GlaxoSmithKline
2024–2028
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Site PI · Recruiting · Phase 3
Takeda
2023–2031
Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study)
Sub-investigator · Recruiting
PSC Partners Seeking a Cure
2024–2031